Anti Tim-3/CD123 CAR-T Cell Therapy(Xuzhou Medical University)

N/A

Report date: 2023/11/13 20:04:07

Base Information

Drug NameAnti Tim-3/CD123 CAR-T Cell Therapy(Xuzhou Medical University)

Drug Alias NameN/A

ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy

Mechanisms of ActionAnti-CD123Anti-Hepatitis A virus cellular receptor 2T lymphocyte replacements

TargetsInterleukin-3 receptor subunit alphaHepatitis A virus cellular receptor 2

Therapy Area/IndicationsLeukemia, Myeloid, Acute

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryMainland China

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaPhase 2 Clinical

Originator CompaniesXuzhou Medical University (Xzmu)The Affiliated Hospital Of Xuzhou Medical University

China Registration ClassN/A

Develop Information

Active CompaniesXuzhou Medical University (Xzmu)

Inactive CompaniesN/A

Active IndicationsLeukemia, Myeloid, Acute

Inactive IndicationsN/A

Other Information

ATC CodeN/A